共 50 条
- [1] Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialJAMA ONCOLOGY, 2023, 9 (02) : 197 - 205Lin, Nancy U.Murthy, Rashmi K.Abramson, VandanaAnders, CareyBachelot, ThomasBedard, Philippe L.Borges, VirginiaCameron, DavidCarey, Lisa A.Chien, A. JoCurigliano, GiuseppeDiGiovanna, Michael P.Gelmon, KarenHortobagyi, GabrielHurvitz, Sara A.Krop, IanLoi, ShereneLoibl, SibylleMueller, VolkmarOliveira, MafaldaPaplomata, ElisavetPegram, MarkSlamon, DennisZelnak, AmeliaRamos, JorgeFeng, WentaoWiner, Eric
- [2] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)CANCER RESEARCH, 2022, 82 (04)Lin, Nancy U.Murthy, Rashmi K.Abramson, VandanaAnders, CareyBachelot, ThomasBedard, PhilippeBorges, VirginiaCameron, DavidCameron, DavidCarey, LisaChien, A. JoCurigliano, GiuseppeDiGiovanna, MichaelGelmon, KarenHortobagyi, GabrielHurvitz, SaraKrop, IanLoi, ShereneLoibl, SibylleMueller, VolkmarOliveira, MafaldaPaplomata, ElisavetPegram, MarkSlamon, DennisZelnak, AmeliaRamos, JorgeFeng, WentaoWiner, Eric
- [3] Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)ANNALS OF ONCOLOGY, 2020, 31 : S62 - S63Curigliano, G.Murthy, R.Loi, S.Okines, A.Paplomata, E.Hamilton, E.Hurvitz, S. A.Cameron, D.Borges, V.Bedard, P.Oliveira, M.Jakobsen, E. H.Bachelot, T.Shachar, S. S.Mueller, V.Carey, L. A.Loibl, S.Feng, W.Walker, L. N.Winer, E.
- [4] Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer with brain metastases (HER2CLIMB).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Lin, Nancy U.Murthy, Rashmi KrishnaAnders, Carey K.Borges, Virginia F.Hurvitz, Sara A.Loi, ShereneAbramson, Vandana G.Bedard, Philippe L.Oliveira, MafaldaZelnak, Amelia BruceDiGiovanna, MichaelBachelot, ThomasChien, Amy JoO'Regan, RuthWardley, Andrew M.Mueller, VolkmarCarey, Lisa A.McGoldrick, Suzanne M.An, GraceWiner, Eric P.
- [5] Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer (MBC) with brain metastases (BM) (HER2CLIMB)ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 161 - 161Mueller, VLin, N.Murthy, R.Anders, C.Borges, VHurvitz, S.Loi, S.Abramson, VBedard, P.Oliveira, M.Zelnak, A.Di Giovanna, M.Bachelot, T.Chien, A. J.O'Regan, R.Wardley, A.Carey, L.McGoldrick, S.An, X.Winer, E. P.
- [6] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 134Mueller, VCurigliano, G.Borges, VHamilton, E.Hurvitz, S.Loi, S.Murthy, R.Okines, A.Paplomata, E.Cameron, D.Carey, L. A.Gelmon, K.Hortobagyi, G.Krop, ILoibl, S.Pegram, M.Slamon, D.Ramos, J.Feng, W.Winer, E.
- [8] Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)CANCER RESEARCH, 2020, 80 (04)Murthy, RashmiLoi, ShereneOkines, AliciaPaplomata, ElisavetHamilton, ErikaHurvitz, SaraLin, NancyBorges, VirginiaAbramson, Vandana GuptaAnders, CareyBedard, Philippe L.Oliveira, MafaldaJakobsen, ErikBachelot, ThomasShachar, Shlomit S.Mueller, VolkmarBraga, SofiaDuhoux, Francois P.Greil, RichardCameron, DavidCarey, LisaCurigliano, GiuseppeGelmon, KarenHortobagyi, GabrielKrop, IanLoibl, SibyllePegram, MarkSlamon, DennisPalanca-Wessels, Maria CorinnaWalker, LukeFeng, WentaoWiner, Eric
- [9] Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2610 - +Lin, Nancy U.Borges, VirginiaAnders, CareyMurthy, Rashmi K.Paplomata, ElisavetHamilton, ErikaHurvitz, SaraLoi, ShereneOkines, AliciaAbramson, VandanaBedard, Philippe L.Oliveira, MafaldaMueller, VolkmarZelnak, AmeliaDiGiovanna, Michael P.Bachelot, ThomasChien, A. JoO'Regan, RuthWardley, AndrewConlin, AlisonCameron, DavidCarey, LisaCurigliano, GiuseppeGelmon, KarenLoibl, SibylleMayor, JoAlMcGoldrick, SuzanneAn, XuebeiWiner, Eric P.
- [10] Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Curigliano, GiuseppeMueller, VolkmarBorges, Virginia F.Hamilton, Erika P.Hurvitz, Sara A.Loi, ShereneMurthy, Rashmi KrishnaOkines, Alicia Frances ClarePaplomata, ElisavetCameron, David A.Carey, Lisa A.Gelmon, Karen A.Hortobagyi, Gabriel N.Krop, Ian E.Loibl, SibyllePegram, Mark D.Slamon, Dennis J.Ramos, JorgeZhang, ChiyuWiner, Eric P.